Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celgene wins FDA clearance for Phase I placenta-derived stem cell study
Clinical development will begin by the end of the 2008 with the initiation of this Phase I, multi-center clinical trial in the US for patients with moderate-to-severe Crohn’s
Clinical development will begin by the end of the 2008 with the initiation of this Phase I, multi-center clinical trial in the US for patients with moderate-to-severe Crohn’s
The joint effort by Arbor Vita and Becton, Dickinson and Company (BD) is directed at developing a more specific diagnostic for cervical cancer screening. The new cervical cancer
Under the restructured agreement Novartis will make an upfront payment to Xoma of $6.2 million, fully fund all future R&D expenses, reduce existing debt by $7.5 million, pay
Prior to joining NuPathe, Mr Goldan spent more than 15 years in business planning and financial management in the life sciences industry. Mr Goldan’s most recent position was
The US company will be operating out of its office in Research Triangle Park, North Carolina. In addition, the company has appointed Eric Nelson as its global head
The restructuring and workforce reduction are part of the company’s business plan to be cash flow positive by the end of 2010. The company remains fully staffed to
The good laboratory practice, investigational new drug (IND)-enabling toxicology studies conducted for LOR-253 included maximum tolerated dose studies and repeat-dose toxicity studies in rodents and nonrodents. The data
According to the company, the trial also achieved a key secondary endpoint of reducing opioid use for Adlea versus placebo (p=0.012) over the four to 32 hour period.
NuLeusin, 3SBio’s second-generation IL-2, is a genetically modified form of IL-2 possessing improved biochemical properties over naturally occurring IL-2. Clinical trials examined the safety and efficacy of two
The study is a double-blind, placebo-controlled, repeat-dosing multi- center study designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetics with mild